The main aim of the center is to identify new biomarkers and drug targets in cardiovascular disease.
The Cardiovascular Research Group (CRG) was in 2022 awarded a grant from Stiftelsen K. G. Jebsen, thus the K. G. Jebsen Centre for Cardiac Biomarkers was established. The centre conducts high-quality, translational and clinical-epidemiological research with the overarching aim to promote personalized therapy in cardiovascular medicine.
The K. G. Jebsen Centre for Cardiac Biomarkers and the head of the group professor Torbjørn Omland (MD, PhD, MPH). The center is affiliated with the Institute of Clinical Medicine at the University of Oslo and has its core at the Cardiovascular Research Group at Campus Akershus University Hospital.
Goals and Strategy
From the start the ambition of the group has been to conduct high-quality, translational and clinical-epidemiological research with the aim of promoting personalized therapy in cardiovascular medicine.
To achieve this goal the group established an extensive collaborative network with leading investigators, nationally and internationally.
Long term objectives inlcude
- To discover novel cardiovascular disease biomarkers and potential drug targets using both hypothesis-based and unbiased proteomics-based approaches.
- To assess the physiology and pathophysiology of candidate biomarkers and drug targets using experimental models of myocardial ischemia and heart failure.
- To enhance the knowledge and understanding of pathophysiological mechanisms linking subclinical myocardial injury to the risk of heart failure development, cardiac arrhythmias and cardiovascular death.
- To perform investigator-initiated randomized-controlled clinical trials with the aim to prevent subclinical myocardial injury and delay its transition to symptomatic heart failure in cancer patients receiving cardiotoxic therapy.
- To assess the diagnostic and prognostic value of circulating and imaging cardiovascular disease biomarkers in large population-based cohorts, as well as in cohorts of patients with acute coronary syndromes, chronic coronary artery disease, cancer patients receiving cardiotoxic therapy and heart failure.
